SUTRO BIOPHARMA
NASDAQ: STRO (Sutro Biopharma, Inc.)
Kemas kini terakhir: 56 minit lalu16.86
-0.97 (-5.44%)
| Penutupan Terdahulu | 17.83 |
| Jumlah Dagangan | 942,335 |
| Harga / Pendapatan (P/E Ke hadapan) | 10.03 |
| Harga / Jualan (P/S) | 4.31 |
| Harga / Buku (P/B) | 2.11 |
| Julat 52 Minggu |
| Margin Operasi (TTM) | -272.84% |
| EPS Cair (TTM) | -2.92 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 33.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 51.91% |
| Nisbah Semasa (MRQ) | 2.16 |
| Aliran Tunai Operasi (OCF TTM) | -194.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -81.28 M |
| Pulangan Atas Aset (ROA TTM) | -39.55% |
| Pulangan Atas Ekuiti (ROE TTM) | -679.15% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Sutro Biopharma, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -1.67 |
|
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.58% |
| % Dimiliki oleh Institusi | 75.70% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Perceptive Advisors Llc | 30 Jun 2026 | 1,304,846 |
| Bvf Inc/Il | 30 Jun 2026 | 1,251,788 |
| Affinity Asset Advisors, Llc | 30 Jun 2026 | 1,172,487 |
| Samsara Biocapital, Llc | 30 Jun 2026 | 1,062,872 |
| Kynam Capital Management, Lp | 30 Jun 2026 | 872,558 |
| Orbimed Advisors Llc | 30 Jun 2026 | 743,944 |
| Balyasny Asset Management L.P. | 30 Jun 2026 | 711,162 |
| Eventide Asset Management, Llc | 30 Jun 2026 | 585,262 |
| Velan Capital Investment Management Lp | 30 Jun 2026 | 512,160 |
| Woodline Partners Lp | 30 Jun 2026 | 458,029 |
| Adar1 Capital Management, Llc | 30 Jun 2026 | 404,014 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |